O. Can

发表

Efficacy and tolerability of adjuvant therapy in ≥70-year-old patients with T3N0M0 colorectal cancer: An observational study

S. Şahin, Ç. Geredeli, Ş. Cihan, 2020, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Prognostic significance of primary tumor localization in stage II and III colon cancer

Ç. Geredeli, Ş. Cihan, N. Yasar, 2018, World journal of gastrointestinal oncology.

How reliable is the high-volume definition in prostate cancer patients: the potential game-changing role of PSMA

S. Karyağar, S. Arıcı, O. Can, 2022, Nuclear medicine communications.

Triglyceride Response to Oral Glucose Load: Is it Exaggerated in Metabolic Syndrome?

A. Oguz, B. Basok, M. Uzunlulu, 2016 .

The Relationship Between Systemic Immune Inflammation Index and Treatment Response in Renal Cell Carcinoma Patients Treated with Tyrosine Kinase Inhibitors: Results from The Turkish Oncology Group Kidney Cancer Consortium Database

B. Öksüzoğlu, N. Karadurmuş, S. Kılıçkap, 2021 .

Expressions of p53, VEGF C, p21: could they be used in preoperative evaluation of lymph node metastasis of esophageal squamous cell carcinoma?

B. Onal, S. Han, B. Kayhan, 2007, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

The effects of fulvestrant treatment on hormone receptor-positive metastatic breast cancer

Ç. Geredeli, Ş. Cihan, N. Yasar, 2019, The European Research Journal.

Clinical and Pathological Characteristics of Patients with High-Risk Breast Cancer Based on BRCA Mutation Profiles: A Retrospective Study.

Ç. Geredeli, Ş. Cihan, N. Yasar, 2021, European journal of breast health.

The relationship between systemic immune inflammation index and survival in patients with metastatic renal cell carcinomatreated withtyrosine kinase inhibitors

B. Öksüzoğlu, N. Karadurmuş, S. Kılıçkap, 2022, Scientific Reports.

The relationship between pan-immune-inflammation value and survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab in the second line and beyond: a Turkish oncology group kidney cancer consortium (TKCC) study

B. Öksüzoğlu, N. Karadurmuş, S. Kılıçkap, 2022, Journal of Cancer Research and Clinical Oncology.

Effect of Adjuvant Chemotherapy in Stage III Cervical Cancer Patients Treated with Concurrent Chemoradiation: A Multicenter Study

I. Cil, N. Ozyurt, A. Onder, 2022, Oncology Research and Treatment.

Factors Affecting Disease-Free Survival in Operated Nonmetastatic Gastrointestinal Stromal Tumors.

Ç. Geredeli, Ş. Cihan, N. Yasar, 2019, The Journal of surgical research.

Serum fetuin-A and RANKL levels in patients with early stage breast cancer

H. Aral, M. Nazlı, Ç. Afşar, 2022, Journal of medical biochemistry.

Nivolumab in metastatic renal cell carcinoma: results from the Turkish Oncology Group Kidney Cancer Consortium database.

U. Demirci, B. Öksüzoğlu, M. Özgüroğlu, 2021, Future Oncology.

External Validation of a Novel Risk Model in Patients With Favorable Risk Renal Cell Carcinoma Defined by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC): Results From the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database.

U. Demirci, B. Öksüzoğlu, M. Özgüroğlu, 2022, Clinical genitourinary cancer.

Efficacy of Imatinib on Advanced and Refractory Desmoid Tumors: A Retrospective Study

Ç. Geredeli, Ş. Cihan, O. Selvi, 2022, Journal of Oncological Sciences.

Factors Affecting Survival in Neuroendocrine Tumors: A 15-Year Single Center Experience

M. Tambas, Ç. Geredeli, Ş. Cihan, 2018, Asian Pacific journal of cancer prevention : APJCP.

Clinical Features and Prognostic Factors of Metastatic Non-Clear Cell Renal Cell Carcinoma: A Multicenter Study from the Turkish Oncology Group Kidney Cancer Consortium

B. Öksüzoğlu, M. Özgüroğlu, S. Kılıçkap, 2023, Urologia Internationalis.